Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jaguar Health, Inc. - Common Stock (NQ:JAGX)

0.5847 -0.0223 (-3.67%)
Streaming Delayed Price Updated: 3:57 PM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jaguar Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Monday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi
Via ACCESS Newswire
Here are the top movers in Tuesday's session. ↗
Via Chartmill
Unusual volume stocks are being observed in Tuesday's session. ↗
Via Chartmill
Tuesday's session: top gainers and losers ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
Which stocks are moving after the closing bell on Monday? ↗
Via Chartmill
Get insights into the top gainers and losers of Friday's after-hours session. ↗
Via Chartmill
Which stocks are experiencing notable movement on Friday? ↗
Via Chartmill
Curious about the most active stocks on Friday? ↗
Via Chartmill
News headline image
The Surge In Jaguar Health Stock: What&#39;s Happening Now? ↗
Jaguar Health Inc (NASDAQ:JAGX) subsidiary, Napo Pharmaceuticals, has struck a new licensing deal with Woodward Specialty. 
Via Benzinga
Keep an eye on the top gainers and losers in Friday's session. ↗
Via Chartmill
Friday's session: gap up and gap down stocks ↗
Via Chartmill
Get insights into the top gainers and losers of Friday's pre-market session. ↗
Via Chartmill
News headline image
Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts
Via ACCESS Newswire
Unusual volume stocks are being observed in Tuesday's session. ↗
Via Chartmill
News headline image
Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million
Via ACCESS Newswire
News headline image
Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication
Via ACCESS Newswire
News headline image
Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Via ACCESS Newswire
News headline image
Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Via ACCESS Newswire
News headline image
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
Via ACCESS Newswire
News headline image
Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders
Via ACCESS Newswire
News headline image
Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study
Via ACCESS Newswire
News headline image
Get insights into the top gainers and losers of Monday's after-hours session. ↗
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones
Via ACCESS Newswire
News headline image
In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID), Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Clinical Trial
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Tuesday's after hours session: top gainers and losers ↗
As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
News headline image
Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.